The connection between people with genetically defined diseases and our therapies may be the most important connection we make. That’s why we pledge to set prices for our medicines that allow us to reach as many people as possible – ensuring wide access to our medicines for patients today and continued investment in innovation for the patients of tomorrow. Regardless of the price point of our medicines, we recognize that some people, especially the uninsured, will need help funding their therapy. And cost isn’t the only barrier when it comes to accessing therapies. To put medicine within reach, we are committed to offering patient assistance programs tailored to address the needs of each patient community we serve. We’ve developed an access and pricing philosophy that articulates our commitment to access, as well as principles that guide our decision-making and enable us to put this philosophy into action.
Supporting access to
Agios is dedicated to improving the lives of those touched by life-altering genetically defined diseases by providing programs that support individuals throughout their journey and assist patients and their families in exploring and accessing available treatment options.
Our commitment to
(U.S. residents only)
Agios offers the myAgios patient support services program as a single point of engagement for U.S. pyruvate kinase (PK) deficiency patients and caregivers. The program includes disease education and community connections for all PK deficiency patients and caregivers, as well as access support, prescription fulfillment and financial assistance for eligible patients being treated with PYRUKYND® (mitapivat). Patients and their caregivers can enroll in the program to be connected with a dedicated and clinically experienced Patient Support Manager.
Our Global Managed Access Program (EU healthcare providers only)
Our Global Managed Access Program (GMAP) provides a pathway for adult PK deficiency patients receiving care in the EU to have access to PYRUKYND®. Healthcare providers may submit an inquiry on behalf of their patients to Agios for consideration.
Agios is committed to developing innovative treatment options that make a meaningful difference in patients’ lives and fundamentally change the way rare and genetically defined diseases are treated. Learn more about our ongoing trials, including studies that are currently recruiting.
Learn more about our ongoing trials, including studies that are currently recruiting.